for educational and safety purposes
Wakefulness-promoting agents; modafinil, armodafinil, and the adrafinil-style prodrugs used for alertness without classic stimulant jitter.
10 sourced · 10 reference
Adrafinil (CRL-40028) is a prodrug of modafinil and one of the most accessible routes to clean, sustained wakefulness and focus. Once converted by the liver into modafinil, it delivers the same eugeroic, alertness-promoting effect that made modafinil famous, without requiring a prescription in many countries. Marketed originally in Europe as Olmifon, it remains a favorite among those seeking long-lasting, jitter-light energy and mental stamina.
Fladrafinil (CRL-40,941) is a synthetic wakefulness drug from the same French research programme of the 1970s and 1980s that produced modafinil and adrafinil; chemically it is adrafinil with a fluorine atom added to each of its two rings. It was never approved or marketed as a medicine anywhere, and it now circulates online as a research chemical and turns up in products sold as nootropic supplements. The body converts it into flmodafinil, which is what actually produces the effect; that conversion has been demonstrated directly in people, but almost nothing else about the drug has been tested in humans. There are no efficacy trials, no safety studies and no published measurement of what it binds to, so claims that it sharpens focus or that it is several times stronger than adrafinil rest on marketing and a 1984 patent rather than on evidence.
Flmodafinil, also written FL-Modafinil and originally coded CRL-40,940, is a fluorinated analogue of modafinil in which both phenyl rings carry a fluorine. It is a genuinely different molecule from modafinil and not a brand of it, which is worth stating plainly because the two names are routinely sold as though interchangeable. Fladrafinil (CRL-40,941) is its prodrug, standing to flmodafinil roughly as adrafinil stands to modafinil. Vendors commonly claim greater potency and better solubility than modafinil; those claims come from early rodent work and from sellers rather than from human trials.
Modafiendz is a fluorinated, N-methylated analog of the wakefulness agent modafinil, marketed online as a next-generation nootropic alternative. It is built around the same eugeroic blueprint that made modafinil a favorite for focus and sustained alertness, with structural tweaks intended to modify its activity. Because the analog itself has not been formally studied, it is best understood as an experimental research chemical riding on the well-mapped pharmacology of its parent.
Modafinil is a prescription wakefulness-promoting drug, approved in the United States in 1998 for excessive sleepiness caused by narcolepsy, obstructive sleep apnea, and shift work disorder. It works mainly by blocking the dopamine transporter, the protein that clears dopamine out of the synapse; human brain imaging confirms it occupies roughly half of those transporters at ordinary doses, although it binds them far more weakly than classic stimulants do. The evidence that it reduces sleepiness in the three approved sleep disorders is strong and rests on large placebo-controlled trials, but the evidence that it improves thinking in healthy, well-rested people is much weaker; the best meta-analysis found only a small overall effect confined to one narrow memory task. It is a Schedule IV controlled substance in the United States, banned in competition by WADA, and carries warnings for rare but serious skin reactions and for making hormonal birth control less reliable.
Armodafinil is the prescription wakefulness drug sold as Nuvigil; it is one of the two mirror-image halves of modafinil, the longer-lasting half, so it does much the same job at a somewhat lower dose. In the United States it is approved only to reduce excessive sleepiness in adults with narcolepsy, obstructive sleep apnea, or shift work disorder, and the evidence for those three uses is genuinely solid; several 12-week placebo-controlled trials show people stay awake longer, though the benefit is measured in a few extra minutes of resisting sleep rather than a cure. Its one well-supported molecular action is weak blockade of the dopamine transporter, which brain scans confirm happens at ordinary doses; the histamine and orexin explanations that circulate online come from studies of modafinil, not of armodafinil itself. Outside the sleep indications the record thins out fast and is often negative, including a clean phase 3 failure for cancer-related fatigue, and this is a Schedule IV controlled drug carrying a pregnancy registry signal for birth defects.
Hydrafinil, also called 9-fluorenol or 9-hydroxyfluorene, is a simple laboratory chemical that Cephalon tested around 2012 while looking for a successor to the wakefulness drug modafinil; despite the similar sounding name it is not chemically related to modafinil and belongs to a different chemical family. In the single rat experiment that exists it kept animals awake longer than modafinil did at the same injected dose, after which the programme was dropped with no published reason and never reached a human trial. The entire human record is one anti-doping study in which three healthy men each swallowed a single 50 mg dose so that laboratories could learn to detect it in urine; nothing at all has been published on whether it improves alertness, attention or fatigue in people, and nothing has been published on its safety. It is banned in competition by the World Anti-Doping Agency and is not an approved medicine in any country.
Power Duo ModaXL is a 250 mg tablet said to contain both modafinil and armodafinil in a single dose.
Orexin-A, also known as hypocretin-1, is a 33-amino-acid neuropeptide produced by a small population of neurons in the lateral hypothalamus that is central to promoting wakefulness and arousal. It is one of two orexin peptides cut from a single precursor and signals through two G-protein-coupled receptors. Narcolepsy type 1 is essentially an orexin-deficiency disease, in which the roughly 70,000 orexin-producing neurons are selectively destroyed and cerebrospinal-fluid orexin becomes undetectable; this is the rationale for orexin-2 receptor agonists now in clinical trials as the first mechanism-based, replacement-style treatment rather than a symptomatic stimulant. Since its discovery in 1998 the orexin system has become a major target in sleep medicine.
Orexin-B, also known as hypocretin-2, is a 28-amino-acid neuropeptide made in the hypothalamus that, together with orexin-A, promotes wakefulness, arousal, and appetite. It is cut from the same precursor as orexin-A but lacks internal disulfide bonds and preferentially activates the orexin type 2 receptor. That receptor is the target of the dual orexin receptor antagonists suvorexant, lemborexant, and daridorexant, which treat insomnia by blocking the same signaling whose loss causes narcolepsy, making the two conditions pharmacological mirror images; one of these drugs was also reported to acutely lower tau and amyloid-beta in human cerebrospinal fluid. The orexin system was discovered in 1998.
CX-717 is a later, more brain-penetrant ampakine (Cortex Pharmaceuticals, later RespireRx) notable for offsetting sleep-deprivation cognitive decline in nonhuman primates and, at high dose, in humans, plus a distinct adult-ADHD development track. It has a 'low-impact' AMPA-PAM profile.
A dechlorinated mazindol analogue tuned to be a clean noradrenaline reuptake blocker plus a partial orexin-2 agonist; an orexin-forward wake drug aimed at narcolepsy.
Fluorene myristate is an obscure research compound marketed as a nootropic; based on its name and vendor descriptions it appears to be a myristic-acid ester of a fluorene or fluorenol core, likely intended as a lipophilic prodrug or slow-release form of 9-fluorenol (hydrafinil), a weak dopamine reuptake inhibitor and modafinil metabolite. There is no primary peer-reviewed literature on fluorene myristate itself, and even its exact structure and CAS identity are inconsistently reported by suppliers. This entry is therefore deliberately cautious and does not assert mechanisms or effects that have not been demonstrated for this specific molecule.
Irdabisant (CEP-26401) is a potent, highly selective histamine H3 receptor antagonist and inverse agonist developed by Cephalon. Because the H3 receptor is largely an inhibitory autoreceptor and heteroreceptor that restrains release of histamine and other arousal-related neurotransmitters, blocking it disinhibits wake-promoting signaling; in preclinical models irdabisant showed robust wake-promoting activity and improved short-term memory at low doses, alongside favorable central nervous system drug-like properties and high selectivity over other histamine receptor subtypes. It was studied as a candidate cognition-enhancing and wakefulness-promoting agent for conditions such as cognitive impairment and schizophrenia. Early human studies characterized its pharmacokinetics and pharmacodynamics, including dose-dependent effects on sleep, but the compound advanced only into early clinical trials and was never brought to market.
Pitolisant is a histamine H3 receptor antagonist and inverse agonist used to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. By blocking the H3 autoreceptor it boosts the brain's own histamine signalling, which promotes wakefulness and places it among the wake-promoting agents sometimes called eugeroics. Marketed mainly as Wakix, it was approved in the European Union in 2016 and by the United States FDA in 2019, and it is unusual among narcolepsy drugs in not being classified as a controlled substance in the United States.
Solriamfetol is an oral selective dopamine and norepinephrine reuptake inhibitor (a phenylalanine derivative) approved in the United States and European Union to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It is marketed as Sunosi and is a US Schedule IV controlled substance.
Oveporexton (TAK-861), approved by the FDA on 5 August 2026 as Orzeyful; the first oral orexin receptor 2 selective agonist licensed for narcolepsy type 1, and the first approved treatment aimed at the cause of the disease rather than its symptoms.
danavorexton (TAK-925); the first-in-class, injectable OX2R-selective orexin agonist that proved wakefulness can be pharmacologically restored, now aimed at reversing anesthetic and opioid sedation.
TAK-994; the first oral OX2R orexin agonist to show major narcolepsy efficacy in phase 2, halted for dose-dependent liver toxicity, and the direct predecessor to oveporexton (TAK-861).
THN102 is an investigational drug combination that pairs the wakefulness-promoting agent modafinil with a low dose of flecainide, a compound that here acts on the brain's glial support cells. It was developed by the company Theranexus on the premise that inhibiting connexin gap junctions in astrocytes strengthens modafinil's effects. It has been studied chiefly for the excessive daytime sleepiness of narcolepsy and is not an approved medicine.
